ASCO Names John Durant, MD, as Executive VP and Washington Lobbyist

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

WASHINGTON--John Durant, MD, has been named to the newly created position of executive vice president of the American Society of Clinical Oncology (ASCO). Formerly president of ASCO and a member of its board of directors, Dr. Durant will become the society's leading spokesman and advocate in Washington on April 1. He is currently vice president for health affairs and director of the medical school at the University of Alabama at Birmingham.

WASHINGTON--John Durant, MD, has been named to the newly createdposition of executive vice president of the American Society ofClinical Oncology (ASCO). Formerly president of ASCO and a memberof its board of directors, Dr. Durant will become the society'sleading spokesman and advocate in Washington on April 1. He iscurrently vice president for health affairs and director of themedical school at the University of Alabama at Birmingham.

Recent Videos
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
4 experts in this video
4 experts in this video
5 experts are featured in this series
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Related Content